LOWE CHRISTOPHER P.
SEC CIK 1376260 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| QNCX | Quince Therapeutics, Inc. | COO, CFO, Interim CEO | 265.0K | — | $2.59M | 6 | 2021-08-16 | 2022-03-03 |
Most active insiders at QNCX, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Benatti Luca | Dir | — | $173.5K |
| 2 | Hannah Brendan | COO, CCO, CBO | — | — |
| 3 | Thye Dirk | CEO, CMO, Dir | — | — |
LOWE CHRISTOPHER P. made no open-market trades at QNCX in the last 12 months.
Transactions 6
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-03-04 | 2022-03-03 | QNCX | Quince Therapeutics, Inc. | LOWE CHRISTOPHER P. | COO, CFO, Interim CEO | A - Grant | $0.00 | +175.0K | 265.0K | +194% | $0 | |
| D | 2021-11-16 | 2021-11-16 | QNCX | Quince Therapeutics, Inc. | LOWE CHRISTOPHER P. | COO, CFO | M - OptEx | $2.23 | +30.0K | 90.0K | +50% | +$66.9K |
| D | 2021-10-07 | 2021-10-05 | QNCX | Quince Therapeutics, Inc. | LOWE CHRISTOPHER P. | COO, CFO | S - Sale+OE | $98.50 | -4,963 | 60.0K | -8% | -$488.9K |
| D | 2021-10-07 | 2021-10-05 | QNCX | Quince Therapeutics, Inc. | LOWE CHRISTOPHER P. | COO, CFO | M - OptEx | $54.85 | +4,963 | 65.0K | +8% | +$272.2K |
| DM | 2021-08-18 | 2021-08-16 | QNCX | Quince Therapeutics, Inc. | LOWE CHRISTOPHER P. | COO, CFO | S - Sale+OE | $95.31 | -22.0K | 33.2K | -40% | -$2.10M |
| DM | 2021-08-18 | 2021-08-16+ | QNCX | Quince Therapeutics, Inc. | LOWE CHRISTOPHER P. | COO, CFO | M - OptEx | $2.23 | +52.0K | 52.0K | New | +$116.0K |
Purchase Sale Sale after option exercise All abbreviations